On February 13, 2025 Neogap therapeutics reported new study published in the highly ranked scientific journal Gut examines how immune system T cells respond to tumours in patients with advanced liver cancer (HCC) (Press release, Neogap Therapeutics, FEB 13, 2025, View Source;pior-technology-identifies-targets-for-personalised-liver-cancer-immunotherapie,c4104603 [SID1234650258]). Using Neogap Therapeutics’ PIOR software platform, the researchers have identified tumour-specific mutations, which may contribute to the development of personalised immunotherapies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
T cells are central to the body’s defence against cancer but can also contribute to an immunosuppressive environment within the tumour. The study analysed T cells from the liver, lymph nodes, and tumour tissue to identify the most reactive cells to cancer-related neoantigens—tumour-specific proteins formed through mutations that can activate the immune system. Bioinformatic analysis identified 542 potential neoantigens from seven patients, 14 of which were found to induce a strong immune response, particularly in T cells from the liver and lymph nodes.
By using PIOR, the researchers were able to identify neoantigens capable of activating T cells, which in turn can attack the tumour.
"The results demonstrate that PIOR can effectively identify neoantigens with potential for future therapeutic applications," says Associate Professor Anna Pasetto, a researcher at Karolinska Institutet and one of the lead authors of the study. "Data-driven analysis of neoantigens is an important component of the new generation of personalised cancer immunotherapies."
The findings show that T cells from the liver and lymph nodes have properties that may be particularly suitable for future immunotherapies.
"This study aligns with Neogap’s vision to develop the next generation of cell therapies," says Ola Nilsson, Head of Neoantigen Production, Development & Clinical Processing at Neogap and co-author of the study. "PIOR plays a key role in our efforts to identify the most promising neoantigens—an essential part of the development of future precision therapies."
The study provides deeper insights into how T cells respond to neoantigens.
"Our findings reinforce the idea that T cells from lymph nodes may be particularly valuable as source material for generating reactive T cells—an approach already applied in Neogap’s ongoing clinical trial in colorectal cancer, which specifically uses lymph nodes as starting material. These discoveries could have a significant impact on both research and the development of new treatments", says Ola Nilsson.